Metagenomi Therapeutics, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
EPS (Diluted)
$-2
Book Value Per Share
$4
Free Cash Flow Per Share
$-2
Cash Per Share
$1
Revenue Per Share
$1
OCF Per Share
$-2
Return on Equity
-44.7%
Return on Assets
-32.2%
Return on Invested Capital
-38.6%
Current Ratio
7.22
Quick Ratio
7.22
Asset Turnover
0.09
Days Sales Outstanding
7.68
R&D / Revenue
374.6%
SBC / Revenue
47.0%
Capex / Revenue
2.3%
Working Capital
$143M
Net Current Asset Value
$103M
Invested Capital
$159M
OCF / Net Income
1.01
FCF / Net Income
1.02
Accruals Ratio (Sloan)
0.5%
Net Debt
$-42M
Net Debt / EBITDA
0.46
Capex Coverage
-154.86
Tangible Common Equity
$159M
TCE / Total Assets
71.7%
NOPAT
$-76M
Cash ROIC
-45.5%
WC / Revenue
565.7%
Capex / D&A
0.11
Reinvestment Rate
4.9%
Asset Growth vs Revenue Growth
19.9%
Stock Price (FY-end)
$2
Market Cap
$60M
P/E Ratio
-0.69
P/S Ratio
2.39
P/B Ratio
0.38
P/TB Ratio
0.38
P/OCF Ratio
-0.68
P/FCF Ratio
-0.67
FCF Yield
-148.3%
Shareholder Yield
-19.6%
Shares Variation (YoY)
12.8%
Beta (5Y)
0.96
Cost of Equity
9.3%
WACC
9.3%
ROIC - WACC Spread
-47.9%
52W High
$4
52W Low
$1
Trailing Return 1M
1.2%
Trailing Return 6M
0.6%
Trailing Return 1Y
-56.7%
F-Score (Piotroski)
1.00
Z-Score (Altman)
-1.93
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.